India and the United States have intensified bilateral cooperation to dismantle transnational drug-trafficking networks and plug the diversion of chemical precursors used to manufacture synthetic narcotics, the White House said in a readout released on 11 November 2026. The announcement followed the second India-US Drug Policy Executive Working Group meeting, held in New Delhi on 2–3 November.

What Was Agreed

Officials from both governments identified three priority areas: closer intelligence sharing, coordinated law enforcement operations, and tighter safeguards for pharmaceutical supply chains. The two sides also reviewed emerging trafficking threats and agreed on measures to curb drug demand. The White House said sustained, timely intelligence exchanges would be essential as traffickers continued to adapt their methods.

What the Officials Said

ONDCP Director Sara Carter described the cooperation as 'vital to disrupting transnational drug trafficking networks and preventing the diversion of synthetic drugs and chemical precursors into global markets.' US Ambassador to India Sergio Gor struck a sharper note, saying the two countries were delivering 'real operational results — choking off illicit precursor chemicals, securing commercial supply chains, and dismantling the cartels that exploit them.' India's delegation was led by Narcotics Control Bureau (NCB) Director General Anurag Garg, while Debbie Seguin, acting deputy director of the White House Office of National Drug Control Policy (ONDCP), headed the American side.

India's Vision Roadmap and Key Operations

Garg presented India's Vision Roadmap 2026–2029, which shifts enforcement focus from individual drug seizures to mapping and dismantling entire criminal ecosystems — targeting financiers, suppliers, facilitators, and transport networks, alongside financial investigations, prevention, and rehabilitation. Two live enforcement initiatives were discussed at the meeting.

Operation MedMax, conducted in July 2025 using jointly developed intelligence from the NCB and the US Drug Enforcement Administration (DEA), uncovered a syndicate illegally distributing regulated medicines across Asia, North America, Europe, and Australia. The probe was triggered by the seizure of 3.7 kg of tramadol tablets in India. Investigators found the network had exploited an online business-to-business platform, digital payment channels, and international intermediaries to ship drugs without legitimate documentation.

Operation WIPE, launched in April 2026, targets online listings of narcotics controlled under Indian law. According to the NCB, the operation has so far identified 122 instances involving 62 substances, including fentanyl. Investigators monitor publicly accessible websites and have shared lists of controlled substances with digital platforms to help them identify and remove illegal listings.

Voluntary Code of Conduct

Beyond law enforcement operations, both delegations discussed a proposed voluntary code of conduct for the chemical industry, designed to prevent substances used in synthetic drug manufacturing from being diverted out of legitimate commerce. The measure reflects a broader recognition that upstream supply-chain controls are as critical as downstream enforcement.

What Comes Next

The working group's first session was held in Washington on 20–21 January, making this its second formal meeting. Both sides agreed to exchange best practices on targeted enforcement and signalled that the operational tempo would continue to rise. As synthetic drug threats evolve rapidly, the framework is expected to inform future joint operations between the NCB and DEA.